[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2119748T3 - Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. - Google Patents

Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.

Info

Publication number
ES2119748T3
ES2119748T3 ES91104393T ES91104393T ES2119748T3 ES 2119748 T3 ES2119748 T3 ES 2119748T3 ES 91104393 T ES91104393 T ES 91104393T ES 91104393 T ES91104393 T ES 91104393T ES 2119748 T3 ES2119748 T3 ES 2119748T3
Authority
ES
Spain
Prior art keywords
water
pharmaceutical composition
composition containing
drug
slightly soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91104393T
Other languages
English (en)
Inventor
Toru Iwao
Kenichi Hirai
Nobuo Kondoh
Koichi Yamanouchi
Kazumasa Yokoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welfide Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfide Corp filed Critical Welfide Corp
Application granted granted Critical
Publication of ES2119748T3 publication Critical patent/ES2119748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTO FARMACEUTICO QUE CONTIENE UNA DROGA LIGERAMENTE SOLUBLE EN AGUA ADMINISTRABLE POR VIA ORAL, CARACTERIZADO POR UNA MEJORADA ESTABILIDAD Y ABSORCION DE LA DROGA DESDE EL TRAMO DIGESTIVO A LA SANGRE. EL USO DEL COMPUESTO DE LA PRESENTE INVENCION PERMITE UNA REDUCCION DE LA DOSIS DE UNA DROGA LIGERAMENTE SOLUBLE EN AGUA, LO QUE CONDUCE CON EL TIEMPO A UN ALIVIO DE LOS DOLORES Y EFECTOS SECUNDARIOS QUE SUFREN LOS PACIENTES.
ES91104393T 1990-03-23 1991-03-21 Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. Expired - Lifetime ES2119748T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7369590 1990-03-23

Publications (1)

Publication Number Publication Date
ES2119748T3 true ES2119748T3 (es) 1998-10-16

Family

ID=13525612

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91104393T Expired - Lifetime ES2119748T3 (es) 1990-03-23 1991-03-21 Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.

Country Status (8)

Country Link
US (2) US5462951A (es)
EP (1) EP0448091B1 (es)
JP (1) JP3125319B2 (es)
KR (1) KR0180232B1 (es)
CA (1) CA2038744C (es)
DE (1) DE69129918T2 (es)
DK (1) DK0448091T3 (es)
ES (1) ES2119748T3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
WO1995005825A1 (fr) * 1993-08-25 1995-03-02 The Green Cross Corporation Traitement symptomatique des troubles circulatoires
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
AU702030B2 (en) * 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
WO1998005310A1 (fr) * 1996-08-02 1998-02-12 Hisamitsu Pharmaceutical Co., Inc. Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale
JP2002511099A (ja) * 1997-07-29 2002-04-09 ファルマシア・アンド・アップジョン・カンパニー 親油性化合物用の自己乳化性処方
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE69927708T2 (de) * 1998-12-23 2006-07-06 Alza Corp., Mountain View Dosierungsformen, die poröse partikel enthalten
US6525058B1 (en) * 1999-06-18 2003-02-25 Yamanouchi Pharmaceutical Co., Ltd Pharmaceutical composition for oral use
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
CN100579514C (zh) 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5618914A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Ubidecarenone composition having good absorbability
EP0031603A1 (en) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmaceutical composition of matter
JPS5764609A (en) * 1980-10-09 1982-04-19 Nissan Chem Ind Ltd Cyclophosphamide composition for rectal administration
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
EP0466197A1 (en) * 1984-05-23 1992-01-15 Green Cross Corporation A lipoxygenase inhibitor
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS6147477A (ja) * 1984-08-14 1986-03-07 Kowa Co 新規１，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
DE3437599C2 (de) * 1984-10-13 1987-04-16 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende Weichgelatinekapseln
US4595690A (en) * 1985-02-11 1986-06-17 Syntex (U.S.A.) Inc. Antihypertensive dihydropyridine derivatives
JPH0686429B2 (ja) * 1986-08-27 1994-11-02 株式会社ミドリ十字 ジヒドロピリジン誘導体
JPS63126819A (ja) * 1986-11-17 1988-05-30 Kao Corp 坐剤基剤及びそれを含有する坐剤
JPH01149764A (ja) * 1987-12-07 1989-06-12 Green Cross Corp:The ビス−ｓ−アルキルベンゼン誘導体
CA1326995C (en) * 1988-01-29 1994-02-15 Kozo Kurihara Cyclosporin compositions
IL89049A0 (en) * 1988-01-29 1989-08-15 Merrell Dow Pharma Pharmaceutical composition containing 4-aroylimidazol-2-ones
US5124340A (en) * 1989-06-28 1992-06-23 The United States Of America As Represented By The Department Of Health And Human Services Use of calcium channel blocker to prevent cocaine induced craving and reinforcement

Also Published As

Publication number Publication date
EP0448091A3 (en) 1993-03-10
EP0448091B1 (en) 1998-08-05
US5462951A (en) 1995-10-31
KR0180232B1 (ko) 1999-03-20
CA2038744A1 (en) 1991-09-24
US5610169A (en) 1997-03-11
DE69129918D1 (de) 1998-09-10
EP0448091A2 (en) 1991-09-25
JP3125319B2 (ja) 2001-01-15
JPH04217912A (ja) 1992-08-07
KR910016332A (ko) 1991-11-05
CA2038744C (en) 2002-01-08
DK0448091T3 (da) 1999-05-03
DE69129918T2 (de) 1999-02-04

Similar Documents

Publication Publication Date Title
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
NO171145C (no) Fremgangsmaate for fremstilling av en fettemulsjon med et hydrofobt medikament
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
FI940787A (fi) Annostusmuoto lääkkeen annostelemiseksi lyhyessä ajanjaksossa
SE8100276L (sv) Farmaceutiskt aktiv komposition omfattande ketoner och heterocykliska foreningar
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
KR970025615A (ko) 암 전이 억제제
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
KR890004705A (ko) 항바이러스성 제제
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
EP0093497A3 (en) Anthelmintic treatment

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 448091

Country of ref document: ES